In addition, LGALS1 expression is also involved in patients’ drug resistance; in fact, this gene is included in a 23 genes signature that distinguishes bortezomib-resistant MM mouse cell line from bortezomib-sensible cell line and significantly predicts differences in patient’s outcomes after treatment with bortezomib [115]. Here, LGALS1 is linked to Miyoshi myopathy.